SS-31 (elamipretide): the mitochondria-targeting peptide in trials
A peptide aimed at the cell's power plant, with promising biology and unfinished proof.
TL;DR
- SS-31 (elamipretide) is a peptide designed to reach failing mitochondria.
- It may help the cell's power plants run with less waste and damage.
- It is investigational, not FDA-approved, and trial results are mixed.
What it is
SS-31 (in plain English: elamipretide, a small peptide that targets the inside of mitochondria) goes after a specific address in the cell. Mitochondria (in plain English: the tiny power plants that turn food and oxygen into energy) wear down with age and disease. Most compounds cannot reach their inner workings. SS-31 is built to slip inside and concentrate there, which is what makes it unusual (PubMed, SS-31 cardiolipin research).
How it works
Imagine a power plant whose inner walls are warping, so it leaks energy and throws off sparks. Those inner walls are shaped by a fat called cardiolipin (in plain English: a structural fat unique to mitochondria). SS-31 binds to cardiolipin and helps hold the walls in their proper folds. With the structure stabilized, the plant can make energy more cleanly and spill fewer damaging byproducts (NIH/PMC review). It is less an accelerator and more a repair crew for the building itself.
Who asks about it
People come to SS-31 when they are reading about why energy fades with age. Some have a family history of muscle or heart conditions tied to mitochondria; others are simply chasing the deeper "why" behind midlife fatigue. They have usually seen the word "mitochondria" promised as the key to everything online. The honest question underneath is good: is there really a way to fix the power plants, or is that just a slogan?
What the research says
The biology is genuinely interesting, and the trial record is genuinely mixed. Elamipretide has been studied in conditions involving damaged mitochondria, including certain heart and muscle diseases. Some early measures looked encouraging (NIH/PMC review). But several larger trials did not meet their main goals. That is a sobering and important result. In plain terms: the target is real and the science is serious, yet the proof that it reliably helps people is not settled. That tension is the current state of play.
What to know before considering it
Keep expectations grounded. SS-31 is investigational, not FDA-approved, and it is not something to source from gray-market sellers. The mixed trial outcomes mean it has not earned a place as an everyday longevity tool, despite how it is marketed. Anyone interested should follow the published trials rather than the hype, and discuss real options with a licensed clinician. For most people, the proven mitochondrial boosters remain unglamorous: exercise, sleep, and not smoking.
The Halftime POV
We are drawn to SS-31 as a window into where longevity medicine is heading, not as a product to push. A compound can have beautiful biology and still need years more evidence before it earns trust. That is exactly the kind of nuance we want to hand you straight. Watch this one with curiosity, keep doing the basics that already work, and let the trials finish the sentence.
Related reading:
- The hallmarks of aging, mapped to peptides
- Longevity peptides vs. supplements: the evidence
- NAD+: what it is and why it matters
FAQ
Q: What is SS-31 (elamipretide)? A: SS-31, or elamipretide, is a small peptide designed to reach the inside of mitochondria, the cell's power plants, and help them run more efficiently. It is being studied in trials, not sold as an approved drug.
Q: Is elamipretide FDA-approved? A: No. Elamipretide is investigational. It has been tested for several conditions with mixed results and is not an FDA-approved medication.
Q: How is SS-31 thought to work? A: It binds to cardiolipin, a fat that shapes the mitochondria's inner membrane. By stabilizing that structure, it may help the power plant make energy with less leakage and damage.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved, and investigational compounds are not approved for general use. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
What is SS-31 (elamipretide)?
SS-31, also called elamipretide, is a small peptide designed to reach the inner part of mitochondria, the cell's power plants, and help them run more efficiently. It is being studied in clinical trials, not sold as an approved drug.
Is elamipretide FDA-approved?
No. Elamipretide is investigational. It has been tested in trials for several conditions with mixed results and is not an FDA-approved medication.
How is SS-31 thought to work?
It binds to cardiolipin, a fat that helps shape the mitochondria's inner membrane. By stabilizing that structure, it may help the power plant produce energy with less leakage and damage.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.